{"id":2387,"date":"2017-08-31T07:25:05","date_gmt":"2017-08-31T07:25:05","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=2387\/"},"modified":"2017-08-31T07:25:30","modified_gmt":"2017-08-31T07:25:30","slug":"europe-new-low-risk-criteria-published","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/","title":{"rendered":"EUROPE: New Low Risk criteria published"},"content":{"rendered":"<p><span style=\"font-weight: 400\">The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new criteria entered into force on 28 August 2017 (Regulation (EU) 2017\/1432).<\/span><\/p>\n<p><span style=\"font-weight: 400\">Two categories are introduced (active substances other than micro-organisms and micro-organisms) and the criteria are clarified. \u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">A major benefit for active substances identified as low risk is that they are approved for 15 years instead of the normal 10 years for first approval. As a result, the maximum authorisation period for products based on these substances are also longer: up to 15 years. In addition, longer data protection up to 15 years can be granted accordingly and there are advertising provisions for low-risk products.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Currently, only 10 active substances are officially recognised as low risk active substances in accordance with Regulation (EC) 1107\/2009 (<\/span><i><span style=\"font-weight: 400\">Bacillus amyloliquefaciens<\/span><\/i><span style=\"font-weight: 400\"> strain FZB24, Cerevisane, COS-OGA, Ferric phosphate, <\/span><i><span style=\"font-weight: 400\">Isaria fumosorosea<\/span><\/i><span style=\"font-weight: 400\"> Apopka strain 97 (formerly <\/span><i><span style=\"font-weight: 400\">Paecilomyces fumosoroseus<\/span><\/i><span style=\"font-weight: 400\">), Mild Pepino Mosaic Virus isolate VC 1, Mild Pepino Mosaic Virus isolate VX 1, Pepino mosaic virus strain CH2 isolate 1906, <\/span><i><span style=\"font-weight: 400\">Saccharomyces cerevisiae<\/span><\/i><span style=\"font-weight: 400\"> strain LAS02 and <\/span><i><span style=\"font-weight: 400\">Trichoderma atroviride<\/span><\/i><span style=\"font-weight: 400\"> strain SC1).<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b>To download: <\/b><a href=\"http:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32017R1432&amp;from=EN\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400\">Commission Regulation (EU) 2017\/1432 of 7 August 2017 amending Regulation (EC) No 1107\/2009 of the European Parliament and the Council concerning the placing of plant protection products on the market as regards the criteria for the approval of low-risk active substances<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><b>Lynxee consulting<\/b><span style=\"font-weight: 400\">\u2019s team is at your disposal to answer your questions.<\/span><\/p>\n<p><b>Contact us!<\/b> <a href=\"https:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400\">https:\/\/lynxee.consulting\/en\/contact\/<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new criteria<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":6,"featured_media":2384,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[223],"class_list":["post-2387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-low-risk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUROPE: New Low Risk criteria published - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE: New Low Risk criteria published - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-31T07:25:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-31T07:25:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Florence Dupeuble\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Florence Dupeuble\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/\"},\"author\":{\"name\":\"Florence Dupeuble\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/c158e1e5ec125a45877f1172fde8a2a5\"},\"headline\":\"EUROPE: New Low Risk criteria published\",\"datePublished\":\"2017-08-31T07:25:05+00:00\",\"dateModified\":\"2017-08-31T07:25:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/\"},\"wordCount\":236,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/tomato-2556426_1920.jpg\",\"keywords\":[\"low risk\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/\",\"name\":\"EUROPE: New Low Risk criteria published - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/tomato-2556426_1920.jpg\",\"datePublished\":\"2017-08-31T07:25:05+00:00\",\"dateModified\":\"2017-08-31T07:25:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/c158e1e5ec125a45877f1172fde8a2a5\"},\"description\":\"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\\\/2009. These new\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/tomato-2556426_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/08\\\/tomato-2556426_1920.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-low-risk-criteria-published\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE: New Low Risk criteria published\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/c158e1e5ec125a45877f1172fde8a2a5\",\"name\":\"Florence Dupeuble\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g\",\"caption\":\"Florence Dupeuble\"},\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/florence\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE: New Low Risk criteria published - Lynxee consulting","description":"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE: New Low Risk criteria published - Lynxee consulting","og_description":"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new","og_url":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/","og_site_name":"Lynxee consulting","article_published_time":"2017-08-31T07:25:05+00:00","article_modified_time":"2017-08-31T07:25:30+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg","type":"image\/jpeg"}],"author":"Florence Dupeuble","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Florence Dupeuble","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/"},"author":{"name":"Florence Dupeuble","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/c158e1e5ec125a45877f1172fde8a2a5"},"headline":"EUROPE: New Low Risk criteria published","datePublished":"2017-08-31T07:25:05+00:00","dateModified":"2017-08-31T07:25:30+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/"},"wordCount":236,"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg","keywords":["low risk"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/","url":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/","name":"EUROPE: New Low Risk criteria published - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg","datePublished":"2017-08-31T07:25:05+00:00","dateModified":"2017-08-31T07:25:30+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/c158e1e5ec125a45877f1172fde8a2a5"},"description":"The EU Commission has just set new approval criteria for low risk active substances, amending Annex II Point 5 of Regulation (EC) 1107\/2009. These new","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/08\/tomato-2556426_1920.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-new-low-risk-criteria-published\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE: New Low Risk criteria published"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/c158e1e5ec125a45877f1172fde8a2a5","name":"Florence Dupeuble","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7282b6b2cb13e8a8dce05b02d54b5191fc5c3736e7920212ea5eea79d548ba15?s=96&d=mm&r=g","caption":"Florence Dupeuble"},"url":"https:\/\/lynxee.consulting\/en\/author\/florence\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=2387"}],"version-history":[{"count":1,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2387\/revisions"}],"predecessor-version":[{"id":2388,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2387\/revisions\/2388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/2384"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=2387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=2387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=2387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}